JP2025512515A - インフルエンザ感染症を予防又は治療するための組成物 - Google Patents

インフルエンザ感染症を予防又は治療するための組成物 Download PDF

Info

Publication number
JP2025512515A
JP2025512515A JP2024560788A JP2024560788A JP2025512515A JP 2025512515 A JP2025512515 A JP 2025512515A JP 2024560788 A JP2024560788 A JP 2024560788A JP 2024560788 A JP2024560788 A JP 2024560788A JP 2025512515 A JP2025512515 A JP 2025512515A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
chimeric protein
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512515A5 (https=
Inventor
チェン リュー，
ジヨウ サイ，
ホンビン ジャン，
ジユアン ヤン，
グワンヤン ション，
ルー ジン，
ジンユン チェン，
モータオ リュー，
ワーナー グリーン，
Original Assignee
インビジシールド テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インビジシールド テクノロジーズ リミテッド filed Critical インビジシールド テクノロジーズ リミテッド
Publication of JP2025512515A publication Critical patent/JP2025512515A/ja
Publication of JP2025512515A5 publication Critical patent/JP2025512515A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
JP2024560788A 2022-04-14 2023-04-13 インフルエンザ感染症を予防又は治療するための組成物 Pending JP2025512515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263331100P 2022-04-14 2022-04-14
US63/331,100 2022-04-14
PCT/US2023/065734 WO2023201306A1 (en) 2022-04-14 2023-04-13 Compositions for preventing or treating influenza infections

Publications (2)

Publication Number Publication Date
JP2025512515A true JP2025512515A (ja) 2025-04-17
JP2025512515A5 JP2025512515A5 (https=) 2026-04-21

Family

ID=88330391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560788A Pending JP2025512515A (ja) 2022-04-14 2023-04-13 インフルエンザ感染症を予防又は治療するための組成物

Country Status (5)

Country Link
US (2) US12459988B2 (https=)
EP (1) EP4508077A4 (https=)
JP (1) JP2025512515A (https=)
CA (1) CA3256034A1 (https=)
WO (1) WO2023201306A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850510A2 (en) * 2012-05-18 2015-03-25 Apple Inc. Device, method, and graphical user interface for manipulating user interfaces based on fingerprint sensor inputs
WO2025142818A1 (ja) * 2023-12-27 2025-07-03 遠友ファーマ株式会社 融合タンパク質、複合体およびその応用
EP4684804A1 (en) * 2024-07-26 2026-01-28 Freie Universität Berlin Conjugation product comprising an antigen binding moiety and a mucin binding moiety

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
WO2008016729A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
RU2010127156A (ru) * 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
CN105490420B (zh) 2010-06-25 2018-01-12 菲舍尔和佩克尔应用有限公司 马达转子、马达、包含该转子的电器和该转子的制造方法
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012109363A2 (en) * 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US8961978B2 (en) * 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
AU2011373387B2 (en) 2011-07-18 2017-06-29 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
EP2785737A2 (en) 2011-12-02 2014-10-08 AIMM Therapeutics B.V. Influenza a virus specific antibodies
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
WO2018140456A1 (en) 2017-01-24 2018-08-02 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)
WO2018148447A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
EP3625251A1 (en) 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
US11780907B2 (en) 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
WO2019169231A1 (en) 2018-03-02 2019-09-06 The University Of Chicago Methods and composition for neutralization of influenza
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
EP3841110A1 (en) 2018-08-23 2021-06-30 Vanderbilt University Human monoclonal antibodies to a new universal influenza a hemagglutinin head domain epitope
CN111423507B (zh) 2019-01-10 2022-04-15 中国科学院分子细胞科学卓越创新中心 广谱性中和流感病毒的全人抗体
KR20210126641A (ko) 2019-02-12 2021-10-20 리제너론 파아마슈티컬스, 인크. 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2020221450A1 (en) 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection
JP7634231B2 (ja) 2019-05-31 2025-02-21 ワシントン ユニバーシティ Ｐａｎ－ノイラミニダーゼ阻害抗体
US20220298230A1 (en) 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections
US11053724B2 (en) 2019-07-23 2021-07-06 Tony AWAD Device to assist in closing doors
US11448049B2 (en) 2019-09-05 2022-09-20 Flowco Production Solutions, LLC Gas assisted plunger lift control system and method
IL292353A (en) 2019-10-28 2022-06-01 Regeneron Pharma Anti-haemagglutinin antibodies and methods of using them
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
EP4100054A4 (en) * 2020-02-07 2024-07-17 Washington University PROTECTIVE ANTIBODIES AGAINST INFLUENZA B
JP2023519105A (ja) 2020-02-11 2023-05-10 ヴァンダービルト ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
EP4107169A4 (en) 2020-02-18 2024-07-17 The University of North Carolina at Chapel Hill CAPSID-AAV PROMOTER INTERACTIONS AND CELL SELECTIVE GENE EXPRESSION
TWI818236B (zh) 2020-02-19 2023-10-11 美商聯合生物醫學公司 用於檢測、預防和治療新型冠狀病毒(covid-19)疾病的設計胜肽及蛋白質
CN111704665B (zh) 2020-02-20 2022-04-01 南京农业大学 一种针对H3N2犬流感病毒的重组犬源化抗体scFv-Fc
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
MX2022011142A (es) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
CN111303280B (zh) 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用
AU2021244774A1 (en) 2020-03-23 2022-09-29 Monash University Antisense oligomers for treatment of disease
WO2021195326A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
US20230122364A1 (en) 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides
JP2023537470A (ja) 2020-08-03 2023-09-01 ヤンセン バイオテツク，インコーポレーテツド ウイルス治療における多方向バイオ輸送のための材料及び方法
WO2022075667A1 (ko) 2020-10-05 2022-04-14 한양대학교 산학협력단 안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물
EP4228697A4 (en) 2020-10-16 2025-01-01 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections

Also Published As

Publication number Publication date
US20250034235A1 (en) 2025-01-30
EP4508077A1 (en) 2025-02-19
US12459988B2 (en) 2025-11-04
CA3256034A1 (en) 2023-10-19
WO2023201306A1 (en) 2023-10-19
EP4508077A4 (en) 2026-03-25
US20260116954A1 (en) 2026-04-30

Similar Documents

Publication Publication Date Title
US20230129210A1 (en) Binding proteins useful against ace2-targeted viruses
US10800835B2 (en) HA binding agents
JP6595448B2 (ja) 治療効率の増強のために鼻腔内送達する中和抗体に基づく組成物および方法
US12459988B2 (en) Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections
US11440952B2 (en) Compositions for preventing or treating viral and other microbial infections
CA3202566A1 (en) Neutralizing monoclonal antibodies against covid-19
US12460193B2 (en) Compositions for preventing or treating coronavirus infections
Tiruthani et al. Engineering a “muco‐trapping” ACE2‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID‐19
WO2026030503A2 (en) Compositions and methods for preventing the spread of viruses
HK40064110A (en) Compositions for preventing or treating viral and other microbial infections
HK40035221A (en) Novel ha binding agents
HK1208619B (en) Novel ha binding agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260413